Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, robotic medical device maker Hansen Medical (Nasdaq: HNSN) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Hansen's business and see what CAPS investors are saying about the stock right now.

Hansen facts

Headquarters (Founded) Mountain View, Calif. (2002)
Market Cap $198 million
Industry Health-care equipment
Trailing-12-Month Revenue $22.1 million
Management CEO Bruce Barclay (since 2010)
CFO Peter Mariani (since 2011)
Return on Equity (Average, Past 3 Years) (102.1%)
Cash/Debt $52.2 million / $29.1 million
Competitors Boston Scientific
Johnson & Johnson

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 95% of the 593 members who have rated Hansen believe the stock will outperform the S&P 500 going forward.  

This month, one of those Fools, GekkoJunior, nicely summed up the bull case for our community:

[Hansen] sells disruptive technology. ... After a long period of marketing, hospitals are starting to enter in to deals with the company to use their products -- most notably a robotic catheter placement system. The chart is showing a nice "cup with a handle pattern" with support around $3.50. I own shares in the company; it is my favorite speculative investment.

If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite a strong four-star rating, Hansen may not be your top choice.

We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2012." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now 

Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of and creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.